Drug intelligence / Profile preview

Yun-Pi-Yi-Shen-Tong-Du-Tang

Development stage: Unknown
Lead developer: Prof. Chengping Wen
Administration: Oral

Overview

Yun-Pi-Yi-Shen-Tong-Du-Tang is an empirical Traditional Chinese Medicine (TCM) formula created by Prof. Chengping Wen, following the academic theory of "invigorating spleen and kidney, dredging collaterals" advanced by Zhu Liang Chun[2][3]. It is intended as a complementary treatment for ankylosing spondylitis (AS) and consists of 11 medicinal herbs, grouped according to TCM principles into "monarch" and "assistant" components. Major herbs include Atractylodes Lancea, Radix Astragali, Glycyrrhiza (to strengthen the spleen), Achyranthes Bidentata (to strengthen kidneys), Rhizoma Smilacis Glabrae, and Aconitum Carmichaeli (to dredge governor vessel). Network pharmacology and protein interaction analyses suggest the mechanism involves modulation of the TLR (Toll-like receptor) signaling pathway and T cell receptor signaling pathway, with key molecular targets identified such as JAK2, STAT3, HSP90AA1, TNF, and PTEN[2][3]. The formula contains over 350 active ingredients and has demonstrated efficacy and favorable safety for AS in retrospective clinical studies[2][3]. The developer is Prof. Chengping Wen, with formulation adjustments over more than two decades for clinical stability and minimized side effects.

Brand names: Yun-Pi-Yi-Shen-Tong-Du-Tang
Other names: Yun-Pi-Yi-Shen-Tong-Du-Tang

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)TLR (Toll-like receptors)HSP90AA1 (Heat shock protein HSP90-alpha)γδ TCR (T-cell receptor)JAK2 (Janus kinase 2)PTEN (Phosphatase and tensin homolog deleted on chromosome ten)

Beyond the preview

Go deeper on Yun-Pi-Yi-Shen-Tong-Du-Tang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yun-Pi-Yi-Shen-Tong-Du-Tang.

Explore the full profile